Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment

Transfusion

Volumn 55, Issue 5, 2015, Pages 1067-1074

  Quinti, Isabella ^a   Pulvirenti, Federica ^a   Milito, Cinzia ^a   Granata, Guido ^a   Giovannetti, Gianluca ^b   La Marra, Fabiola ^a   Pesce, Anna M ^a   Farrugia, Albert ^c,d,e   Coluzzi, Serelina ^b   Girelli, Gabriella ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Plasma Protein Therapeutics Association   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD GROUP A ANTIBODY; IMMUNOGLOBULIN; PREDNISONE; RHESUS C ANTIBODY; RHESUS D ANTIBODY; STEROID; IMMUNOGLOBULIN G;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BACKACHE; DRUG DOSE REDUCTION; DRUG FEVER; ELUTION; FATIGUE; FEMALE; GRAFT RECIPIENT; HEMOLYSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; JAUNDICE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PALLOR; TACHYCARDIA; ADOLESCENT; CHILD; ERYTHROCYTE; PHYSIOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; IMMUNOGLOBULIN G; MALE; OBSERVATIONAL STUDIES AS TOPIC; OBSERVATIONAL STUDY AS TOPIC; YOUNG ADULT;

EID: 84929275166     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12939     Document Type: Article

References (31)

1. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525-553.
2. Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010;135:255-263.
3. Cunningham-Rundles C,. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin Exp Immunol 2011;164 Suppl 2:16-19.
4. Thorpe SJ, Fox BJ, Dolman CD, et al. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sang 2003;85:80-84.
5. Baxley A, Akhtari M,. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2011;11:1663-1667.
6. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48:1598-1601.
7. Rodeghiero F, Schiavotto C, Castaman G, et al. A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and antiD immunoglobulins. Haematologica 1992;77:248-252.
8. Michelis FV, Branch DR, Scovell I, et al. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Transfusion 2014;54:681-690.
9. Schroeder HW Jr, Dougherty CJ,. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection 2012;40:601-611.
10. Desborough MJ, Miller J, Thorpe SJ, et al. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med 2014;24:219-226.
11. Shoham-Kessary H, Naot Y, Gershon H,. Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes. Clin Exp Immunol 1998;113:77-84.
12. Kessary-Shoham H, Levy Y, Shoenfeld Y, et al. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun 1999;13:129-135.
13. Canadian Blood Services. Important information regarding IVIG associated hemolysis. 2009 [cited 2009 July 7]. Available from: http://www.bloodservices.ca/CentreApps/Internet/UW-V502-MainEngine.nsf/resources/CustomerLetters09/$file/CL-2009-02.pdf.
14. Thorpe SJ, Fox BJ, Dolman CD, et al. Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method. Biologicals 2005;33:111-116.
15. Thorpe SJ, Fox B, Sharp G, et al. International collaborative study to evaluate candidate reference reagents to standardize haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulin products. Vox Sang 2009;97:160-168.
16. Conley ME, Notarangelo LD, Etzioni A,. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999;93:190-197.
17. European Directorate for the Quality of Medicines and Healthcare. Human normal immunoglobulin for intravenous administration. European pharmacopoeia. 7th Monograph 0918 ed. Strasbourg (France): Council of Europe; 2011. p. 4166-4168.
18. European Directorate for the Quality of Medicines and Healthcare. Anti-A and anti-B haemagglutinins. European pharmacopoeia. 7th General chapter 2.6.20 ed. Strasbourg (France): Council of Europe; 2011. p. 151-199.
19. European Directorate for the Quality of Medicines and Healthcare. Test for anti-D antibodies in human immunoglobulin. European pharmacopoeia. 7th General chapter 2.6.26 ed. Strasbourg (France): Council of Europe; 2011. p. 3546.
20. Thorpe SJ, Fox B, Heath A, et al. International collaborative study to assess candidate reference preparations to control the level of anti-D in IVIG for use in Europe and the United States. Biologicals 2006;34:209-212.
21. Pintova S, Bhardwaj AS, Aledort LM,. IVIG-a hemolytic culprit. N Engl J Med 2012;367:974-976.
22. Golla S, Horkan C, Dogaru G, et al. Rapid encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura. Acta Haematol 2008;120:100-103.
23. Hudson KE, Lin E, Hendrickson JE, et al. Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. Blood 2010;115:3989-3996.
24. Brittain JE, Parise LV,. Cytokines and plasma factors in sickle cell disease. Curr Opin Hematol 2007;14:438-443.
25. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008;112:277-286.
26. Ochtrop ML, Goldacker S, May AM, et al. T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. Blood 2011;118:309-318.
27. Cunningham-Rundles C,. The many faces of common variable immunodeficiency. Hematology Am Soc Hematol Educ Program 2012;2012:301-305.
28. Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007;27:308-316.
29. Wong GK, Goldacker S, Winterhalter C, et al. Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. Clin Exp Immunol 2013;172:63-72.
30. Romberg V,. Effects of the manufacturing process on anti-A titers in IVIG. Presentation at Workshop "Strategies to Address Hemolytic Complications of Immune Globulin Infusions." US Food and Drug Administration 29 Jaunary 2014, Bethesda, MD, USA.
31. Nardini C,. Anti-A and anti-B haemagglutinin tend analysis during manufacturing process of IVIG. Presentation at Workshop "Strategies to Address Hemolytic Complications of Immune Globulin Infusions." US Food and Drug Administration 29 January 2014, Bethesda, MD, USA.